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Alzheimer's disease is a neurodegenerative illness, so far without cure, that affects an increasing number of 
people around the world. Due to the adverse effects caused by drugs for treating this disease currently in 
clinical use, it is necessary to search for more effective and less aggressive therapeutic resources. In this work 
a modern technological alternative was used to build new drugs useful for the treatment of Alzheimer's 
disease from fungi. This strategy consists on the development of pools of fungal molecules able of act in 
intelligent synergistic mechanisms to block acetylcholinesterase, enzyme involved in the development of 
Alzheimer's disease. Expression of pools containing new secondary metabolites can be achieved by adding 
DNA methyltransferase inhibitors to the fermentative process. This fast in vitro approach was used to build a 
combination of fungal metabolites containing acetylcholinesterase inhibitors. Biosynthesis elicitation was 
achieved by adding DNA methyltransferases inhibitors (hydralazine and procainamide) to solid culture media 
and then filamentous fungi Aspergillus chevalieri, Talaromyces calidicanius, Clonostachys rogersoniana, 
Fusarium nygamai, and Penicillium sp. were added. Straightforward HPLC analysis showed elicitation of new 
compounds by all species, being hydralazine the most effective epigenetic modifier especially towards T. 
calidicanius. Procainamide was able to enable expression of several major new secondary metabolites as for 
A. chevalieri (RT 51 min), and F. nygamai (RT 21.5 min). In general, the pools of molecules expressed after 
epigenetic modulation were more effective in acetylcholinesterase inhibition than the metabolites expressed 
without modulation. Modulation of C. rogersoniana by procainamide increased approximately four times the 
biosynthesis of antiacetylcholinesterase metabolites in relation to the control. T. 
calidicanius and Penicillium species modulated with procainamide produced a pool of metabolites about twice 
more active in regarding to the basal metabolome, while the pool of metabolites from C. rogersoniana and T. 
calidicanius were five and three times more active (40.34 ± 0.15% and 48.54 ± 1.34%, respectively) than the 
non-modulated extracts.  
1 Introduction 
Alzheimer's disease is a neurodegenerative illness of huge social impact that affects an increasing number of 
people worldwide. Currently, most treatments for Alzheimer's disease are based in acetylcholinesterase 
inhibitors since the cure for this pathology is still unknown. Drugs currently in clinical use cause several 
adverse effects, being necessary to search for faster, effective and less aggressive therapeutic strategies able 
to minimize or delay the major symptoms of Alzheimer’s disease (Dey et al., 2017). Research involving fungi 
represents an important role in the discovery for new secondary metabolites, including acetylcholinesterase 
inhibitors (Lima et al., 2018a). Fungi are microorganisms that produce a wide variety of compounds known for 
their biological properties. However, these organisms have silent biosynthetic gene clusters not still expressed 
without biotic or abiotic stimulation (Rutledge and Challis, 2015) and several approaches have been 
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developed to stimulate gene expression in fungi, aiming at production of new biologically active substances 
(Takahashi et al., 2013). 
A modern technological alternative to build new drug leads in this field is the development of pools of fungal 
molecules able to act in intelligent synergic mechanisms to block acetylcholinesterase, increasing 
acetylcholine level in the patients’ brains. Expression of these pools containing new secondary metabolites 
can be achieved by adding histone deacetylases (HDAC) or DNA methyltransferases inhibitors (DNAMT) to 
the fermentative process. These chemical compounds, called epigenetic modifiers, activate the expression of 
silent biosynthetic pathways by fungi (Lima et al., 2018b). In addition to the production of new metabolites, this 
approach may also lead to an increase in the yield of compounds commonly produced under classical 
conditions (Williams et al., 2008), which is extremely important approach to produce metabolites of interest.  
Epigenetic modulation consists in the interaction of these modulators with DNA, causing changes in gene 
expression, through activation of naturally silenced biosynthetic routes (Cherblanc et al., 2013; Chung et al., 
2013). In addition to histone modification, DNA methylation is one of the most well-known gene regulation 
processes (Cherblanc et al., 2013). Methylation of DNA corresponds to an epigenetic modification governed 
by DNA methyltransferases, enzymes responsible for catalyzing the transferring of methyl groups to DNA 
(Cichewicz, 2010), leading to transcriptional repression (Cherblanc et al., 2013). Among the inhibitors of DNA 
methyltransferase, the most used are procainamide hydrochloride (PROCA) and hydralazine hydrochloride 
(HYDRA). In the present work, the modulators PROCA and HYDRA were used for metabolic modulation of 
some species of filamentous fungi (Aspergillus chevalieri, Talaromyces calidicanius, Clonostachys 
rogersoniana, Fusarium nygamai, and Penicillium sp.) in solid culture medium, aiming at the expression of 
new secondary metabolites with acetylcholinesterase inhibitory activity. 
2 Materials and methods 
2.1 Materials 
The reagents used for analysis of AChE inhibition were TRIS/HCl by Invitrogen (Carlsbad, USA); 
acetylthiocholine iodide (ATCI) (Sigma, St. Louis, USA); 5,5'-dithiobis (2-nitro-benzoic acid) (DTNB) (Sigma, 
St. Louis, USA); acetylcholinesterase from Electrophorus electricus, type V-S (Sigma, St. Louis, USA); 
albumin bovine serum (Sigma, St. Louis, USA); and eserine (Sigma, St. Louis, USA). For analysis by HPLC, a 
Shimadzu 20A series high performance liquid chromatograph was used consisting of two LC-20AT pumps, a 
UV-visible SPD-20A detector, Kromazil C18 250 x 4.6 5 μm analytical column Nucleosil C18 250 x 3.0 mm, 5 
μm (Supelco) and data acquisition software LC solution. Procainamide and hydralazine hydrochlorides were 
purchased from Sigma (St. Louis, USA).  Microorganisms used in this study, Aspergillus chevalieri (Ac), 
Talaromyces calidicanius (Tc), Clonostachys rogersoniana (Cr), Penicillium sp. (P) and Fusarium nygamai 
(Fn), were isolated from soil at Embrapa Maize and Sorghum (Minas Gerais, Brazil), where they are deposited 
under the codes BRM047709, BRM047712, BRM047708, BRM047710 and BRM047711, respectively. 
2.2 Epigenetic modulation  
Each fungal species was grown in Petri dishes containing solid culture medium containing bacteriological agar 
(39 g/L) beef extract (10 g/L), glycerin (10 g/L) sterilized at 120 ºC for 20 min (control experiment). Petri dishes 
containing the modulators were prepared with the same culture medium. This medium was sterilized in 
Erlenmeyer flasks and, after cooling to 60 ºC, epigenetic modulators PROCA and HYDRA were added, 
separately, inside a laminar flow cabinet, to achieve a final concentration of 500 μmol/L before pouring into 
Petri dishes (30 mL per plate). After solidification, each fungus was inoculated in triplicate. Controls were 
carried out containing culture medium and the modulators (without inoculation of fungi), to measure possible 
spontaneous degradation of modulators in the culture medium. Fungal cultivation took place for 28 days at 25 
ºC. Then, fungal metabolites were recovered using methanol. In sequence, HPLC metabolic profile and 
acetylcholinesterase inhibitory activity of the resulting extracts were assessed.  
2.3 HPLC analysis 
Fungal extracts obtained as a result of epigenetic modulation, control extracts (basal metabolism), and 
extracts of culture medium containing the modulators (PROCA or HYDRA) were dissolved in HPLC grade 
methanol (1 mg/mL). The following chromatographic conditions were used for HPLC analyses: flow 0.6 
mL/min; injection volume 20 µL; temperature 25 °C; Mobile phase: HPLC grade acetonitrile (A) and ultrapure 
water containing 0.1% formic acid (B). Gradient method: 0.01-5 min, 95% B, 5-30 min, 50% B, 30-45 min, 0% 
B, 45-53 min, 0% B, using A to complete 100%. The chromatograms were monitored at 270 nm.  
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2.4 Acetylcholinesterase inhibition assay 
This assay was carried out based on the methodology described by Ellman et al. (1961), with modifications 
(Dominguete and Takahashi, 2018) and performed in 96-well microplates in quintuplicate. In each well were 
added 25 μL of fungal extracts (10 mg/mL in DMSO), 50 μL of Tris-HCl buffer (50 mM, pH 8.0), 125 μL DTNB 
solution (3 mM), and 25 μL of ATCI solution (15 mM). Eserine (10 mg/mL in DMSO) was used as positive and 
DMSO as negative control. Absorbance was measured (405 nm, Microplate Reader) for eight times, with 
intervals of 1 min. Then, AChE solution (25 µL, 0.22 U/mL in buffer) was added to the wells and absorbances 
were measured ten times at 405 nm, with 1 min intervals. The inhibitory activity of AChE was measured 
following the increase of yellow color resulting from reaction of thiocholine with dithiobisnitrobenzoate ion. 
Percent inhibition was calculated using the formula: Inhibition (%) = 100 - [(RSsample / RBcontrol) * 100], 
where RSsample = rate of sample extracts reaction and RBcontrol = rate of blank.  
2.5 Statistical analysis 
The average percentages of inhibition of the extracts were compared by analysis of variance (single-factor 
ANOVA) followed by Tukey test, with 95 % confidence. Graphpad Prism 5.02 software was used for analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Chromatograms (270 nm) of profiles from the fungal extracts of A. chevalieri (I), T. calidicanius (II),  
Penicillium (III), C. rogersoniana (IV) and F. nygamai (V) obtained before (Ac, Tc, P, Cr and Fn) and after 
induced production of metabolites using procainamide (PROCA) and hydralazine (HYDRA). 
3 Results and Discussion    
3.1 Evaluation of epigenetic modulation via HPLC analysis 
HPLC analysis showed that the addition of DNA methyltransferases inhibitors PROCA and HYDRA during 
cultivation of the fungal species Aspergillus chevalieri (Ac), Talaromyces calidicanius (Tc), Clonostachys 
rogersoniana (Cr), Penicillium sp. (P) and Fusarium nygamai (Fn) promoted expression of new secondary 
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metabolites (Figure 1). Procainamide led the species A. chevalieri to produce a new major metabolite 
(Retention time, RT, 51.0 min, Chromatogram I, Ac + PROCA), not observed in the control (Chromatogram I, 
Ac). Under modulation with hydralazine, this fungus produced metabolites other than those expressed in its 
basal metabolism (control), including a major metabolite (RT 28.5 min) and two minority ones (Chromatogram 
I, Ac + HYDHA) showing that the modulators activated biosynthetic routes silenced, leading to elicitation of 
new compounds. For T. calidicanius, no significant variation was observed in the metabolic profile when 
procainamide was used (Chromatogram II, Tc + PROCA), while modulation with hydralazine resulted in the 
elicitation of several different metabolites. The major new metabolite was found at RT 28.5 min, while minor 
new metabolites were observed in RT 24.5, 26.5, 27.0 and 27.5 min (Chromatogram II, Tc + HYDRA). The 
species Penicillium followed the same pattern, presenting a new major metabolite (RT 21.5 min, 
Chromatogram III, P + PROCA) when grown in the presence of procainamide while addition of hydralazine to 
its growth resulted in a great variation of its metabolic profile (Chromatogram III, P + HYDRA). Modulation of 
C. rogersoniana the same biosynthetic routes were activated by both modulators resulting in identical 
metabolic profiles, with a major metabolite with RT 20.5 min (Chromatogram IV, Cr + PROCA and Cr + 
HYDRA); however, the metabolites produced under modulation were different from those produced by normal 
metabolism (Chromatogram V, Cr). New metabolites were produced by F. nygamai in the presence of the 
epigenetic modulators procainamide (TR 21.5 min, Chromatogram V, Fn + PROCA) and hydralazine (TR 
28.5, 26.6 and 27.0 min, Chromatogram V, Fn + HYDRA). 
Considering the whole experiment, regardless the fungal species utilized, hydralazine provoked higher 
compounds elicitation in relation to the basal fungal metabolism. Although both modulators, PROCA and 
HYDRA act by the same mechanism, i.e., inhibiting DNA-metiltranferases, they activated different biosynthetic 
routes, leading to the expression of new secondary metabolites by most of the same fungal species. This 
efficient change in the rate of genes transcription lead to an expressive metabolic diversification, showing its 
efficiency for the synthesis of new bioactive metabolites by fungi. 
3.2 Acetylcholinesterase inhibitory activity  
Although PROCA and HYDRA provoked a significant expression of new metabolites by the fungal species, an 
enzymatic assay was carried out to understand the role of the new metabolites as acetylcholinesterase 
inhibitors (Figure 2). In fact, epigenetic modulation increased acetylcholinesterase inhibition, since extracts 
obtained in the presence of PROCA and HYDRA were in general more active than their respective controls 
(growth without the modulators), except for A. Chevalieri, the only one that did not exhibit increase in activity, 
although presented variation in its metabolic profile, with production of new compounds, as evidenced by the 
HPLC analysis (Figure 1, Chromatogram I).  
The metabolites from T. calidicanius and Penicillium species grown under modulation with PROCA were about 
twice more active (30.53 ± 1.44% and 37.54 ± 0.92%, respectively) than their respective controls (14.64 ± 
0.51 % and 18.32 ± 0.15%, respectively). Under modulation with HYDRA increase in activity was also 
observed as for T. calidicanius that produced a pool of metabolites about three times more active (48.54 ± 
1.34 %) and for Penicillium twice more active (40.13 ± 0.86%) in relation to the respective controls (P < 
0.0001). The metabolites produced by C. rogersoniana in the presence of PROCA showed significant increase 
in activity (30.88 ± 0.12 %) in relation to control (8.46 ± 0.53 ), while HYDRA-modulated fungus extract was 
even more active (40.34 ± 0.15%) than the control. Although extracts from C. rogersoniana  obtained in the 
presence of PROCA and HYDRA showed very similar metabolic profiles, their effect in acetylcholinesterase 
inhibition varied, as HYDRA-modulated extract was significantly more active. C. rogersoniana  is reported to 
produce terpenes (Dong et al., 2017) and compounds of this class were previously reported as 
acetylcholinesterase inhibitors (Dos Santos et al., 2017).  
Therefore, it is possible that epigenetic modulation by HYDRA increased terpenoid biosynthesis, therefore 
justifying activity increase in comparison to the control.  
Regarding the species F. nygamai, presence of PROCA during its development led to a significant activity 
increase (48.64 ± 0.48%) in relation to the control (38.16 ± 1.45%), whereas HYDRA did not present 
significant difference. Although is expected increase in the biosynthesis of bioactive compounds, metabolic 
modifications caused by epigenetic agents may be either synergistic or antagonistic (Kondo et al., 2003). 
Based on these results, the expression of pools containing new secondary metabolites by addition of DNA 
methyltransferases inhibitors was effective for the species studied, including production of new compounds 
with acetylcholinesterase inhibitory activity.  
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 Figure 2: Acetylcholinesterase inhibitory activity of the fungal metabolites produced after modulation with 
procainamide (PROCA) and hidralazine (HYDRA) in comparison to respective controls. 
As observed, the present approach is a prolific methodology for discovering new routes for production of new 
compounds efficient for increasing blood levels of acetylcholine, which is useful in the symptomatic treatment 
of patients with Alzheimer's disease. Classical search for bioactive fungal metabolites usually focus in the 
isolation and biological screening of pure compounds, which is time consuming and requires the use of large 
volumes of solvents. In addition, the later does not consider the synergism resulting from metabolites pools 
(Chear et al., 2016). On the other side, acetylcholinesterase inhibitors can also be obtained from other natural 
sources. Ethanol extracts from the vegetal species Brassica oleracea var. capitata f. rubra and Cinnamomum 
verum, for instance, inhibited acetylcholinesterase in 49.44 and 63.02%, respectively (Boğa et al., 2011) while 
the ethanol extract of the red algae Grateloupia lancifolia presented 91.1% activity (Nguyen and Kim, 2012). 
Anti-acetylcholinesterase activity of essential oils from plant species Aframomum melegueta, Ocimum 
gratissimum (Owokotomoa et al., 2015), and Hyptis dilatata (Almeida et al., 2018) are also reported. However, 
fungal extracts as source of new acetylcholinesterase inhibitors have the advantage of being easily 
engineered to activate production of bioactive metabolites in processes that can be easily scaled up 
(Takahashi et al., 2008).  
4. Conclusions 
In general, extracts from epigenetically modulated fungi, especially C. rogersoniana and T. calidicanius 
showed greater acetylcholinesterase inhibitory activity than un-modulated ones (control extracts). Therefore, 
chemically engineered fermentation using epigenetic modifiers showed good response towards the species 
studied. Modulation of fungal metabolism resulted in the production of pools of bioactive metabolites, being a 
fast-forward option for the production of novel models of acetylcholinesterase inhibitors.  
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